Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban After Endoscopic Therapy in High-Risk Variceal Bleeding With Portal Vein Thrombosis
ChiCTR2600128107Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in Cirrhosis, esophageal varices, gastric varices and 1 more (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Adverse events. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
Cirrhosisesophageal varicesgastric varicesportal vein thrombosis (PVT)
Beyond the preview
Go deeper on ChiCTR2600128107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128107.